

GPTHEALTH/CS/SE/2024-25

August 13, 2024

The Department of Corporate Services BSE Limited, Phiroze Jeejeebhoy Towers, Dalal Street Mumbai - 400001 Scrip Code: 544131	National Stock Exchange of India Limited Exchange Plaza, Plot no. C/1, G Block, Bandra-Kurla Complex, Bandra (E), Mumbai - 400 051 Scrip Symbol: GPTHEALTH
---	--

Dear Sir/Madam

Subject: Submission of Un-Audited Financial Results for the Quarter ended June 30, 2024:

In Pursuance of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are to inform you that the Board of Directors at their meeting held today i.e. Tuesday, August 13, 2024, have inter-alia considered, approved and taken on record, the Un-Audited Financial Results (Standalone) of the Company for the 1st Quarter ended on June 30, 2024.

A copy of Un-Audited Financial Results (Standalone) along with Limited Review Report of the Statutory Auditors thereon for the 01 Quarter ended on June 30, 2024, as required under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, is enclosed herewith for your record and reference.

For GPT Healthcare Limited

Ankur Sharma
Company Secretary and Compliance Officer
M. No A31833

Encl: A/a

Independent Auditor's Review Report on the Quarterly Unaudited Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**Review Report to
The Board of Directors
GPT Healthcare Limited**

1. We have reviewed the accompanying statement of unaudited financial results of GPT Healthcare Limited (the "Company") for the quarter ended June 30, 2024 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. The Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

S.R. BATLIBOI & Co. LLP

Chartered Accountants

5. The comparative financial information of the Company for the immediately preceding quarter ended March 31, 2024, corresponding quarter ended June 30, 2023 and year ended March 31, 2024 were audited by the predecessor auditor who expressed an unmodified opinion on those financial statements/information on May 21, 2024, September 27, 2023 and May 21, 2024 respectively.

For S.R. BATLIBOI & Co. LLP

Chartered Accountants

ICAI Firm registration number: 301003E/E300005

SANJAY
KUMAR
AGARWAL

Digitally signed by SANJAY
KUMAR AGARWAL
DN: cn=SANJAY KUMAR
AGARWAL, c=IN, o=Personal,
email=agarwsa@gmail.com
Date: 2024.08.13 15:36:01 +05'30'

per Sanjay Kumar Agarwal

Partner

Membership No.: 060352

UDIN: 24060352BKFTGG3470

Kolkata

Date:- August 13, 2024

GPT HEALTHCARE LIMITED

Registered Office: GPT Centre, JC-25, Sector - III, Salt Lake City, Kolkata - 700 106, India
CIN : L70101WB1989PLC047402, Website: www.ilshospitals.com, Email : ghl.cosec@gptgroup.co.in



Statement Of Unaudited Financial Results for the quarter ended June 30, 2024

(₹ in lakhs unless otherwise stated)

	Particulars	Quarter Ended			Year Ended
		30.06.2024	31.03.2024	30.06.2023	31.03.2024
		Unaudited	Audited (Refer Note No 5)	Audited	Audited
1	Income				
	(a) Revenue from operations	9,781.98	9,942.58	9,620.05	40,019.30
	(b) Other income	223.61	159.21	143.38	529.14
	Total Income	10,005.59	10,101.79	9,763.43	40,548.44
2	Expenses				
	(a) Cost of materials consumed	1,834.19	2,078.82	2,008.99	8,296.24
	(b) Employee benefits expense	1,871.98	1,699.75	1,723.28	6,893.47
	(c) Finance costs	86.01	159.40	200.61	710.50
	(d) Depreciation and amortisation expense	468.31	475.87	433.67	1,798.19
	(e) Other expenses	4,278.21	3,846.52	3,981.32	16,045.70
	Total Expenses	8,538.70	8,260.36	8,347.87	33,744.10
3	Profit before tax (1-2)	1,466.89	1,841.43	1,415.56	6,804.34
4	Tax Expense				
	(a) Current tax	259.00	320.00	247.00	1,189.00
	(b) Deferred tax (including MAT Credit utilisation)	211.44	239.80	170.59	838.44
	Total tax expenses	470.44	559.80	417.59	2,027.44
5	Profit after tax (3-4)	996.45	1,281.63	997.97	4,776.90
6	Other Comprehensive Income/ (Loss) (OCI)				
	Items that will not be reclassified to profit or loss				
	(i) Remeasurement of defined benefit plan	0.40	42.53	(35.31)	2.26
	(ii) Income tax relating to above	(0.12)	(12.40)	10.28	(0.66)
	Other Comprehensive Income/ (Loss)	0.28	30.13	(25.03)	1.60
7	Total Comprehensive Income (5+6)	996.73	1,311.76	972.94	4,778.50
8	Paid up equity share capital (face value of ₹10 each)	8,205.48	8,205.48	7,990.43	8,205.48
	[Refer Note No 4]				
9	Other Equity				13,643.55
10	Earnings per equity share (of ₹10 each) :				
	(a) Basic (₹)	1.21*	1.59*	1.25*	5.96
	(b) Diluted (₹)	1.21*	1.59*	1.25*	5.96

The figures marked with () are not annualised

DWARIKA
PRASAD
TANTIA
Digitally signed by
DWARIKA PRASAD
TANTIA
Date: 2024.08.13
15:15:27 +05'30'

Notes:

1. The above unaudited financial results of the Company for the quarter ended June 30, 2024 have been reviewed by the Audit Committee and thereafter approved by the Board of Directors at their respective meetings held on August 13, 2024. These unaudited financial results have been subjected to limited review by the statutory auditors of the Company in accordance with Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015 ("the Regulations") who has issued an unmodified conclusion on these unaudited financial results.
2. The unaudited financial results of the company have been prepared in accordance with the Indian Accounting Standards ('Ind AS') as prescribed under Section 133 of the Companies Act, 2013 read with the Companies (Indian Accounting Standards) Rules, 2015, as amended.
3. The company operates in one single reportable business segment and geographical segment i.e. healthcare service in India.
4. During the quarter and year ended March 31, 2024, GPT Healthcare Limited ("the Company") has completed Initial Public Offering (IPO) comprising of fresh issue of 21,50,537 equity shares and offer for sale from investor selling shareholder of 2,60,82,786 equity shares of face value ₹10 each at an issue price of ₹186 per share for cash consideration aggregating to ₹ 52,513.98 Lakhs. Pursuant to IPO, equity shares of the Company were listed on BSE Limited and National Stock Exchange w.e.f. February 29, 2024.
5. The figures of the quarter ended March 31, 2024 are the balancing figures between audited figures in respect of full financial year upto March 31, 2024 and the unaudited published year-to-date figures upto December 31, 2023 being the date of the end of the third quarter of previous financial year, which were subject to limited review.
6. The above unaudited financial results are also available on the Company's website www.ilshospitals.com and also on the stock exchange websites.

For and on behalf of the Board of Directors

DWARIKA
PRASAD
TANTIA

Digitally signed by
DWARIKA PRASAD
TANTIA
Date: 2024.08.13
15:15:46 +05'30'

Dwarika Prasad Tantia

Executive Chairman

DIN : 00001341

Place : Kolkata

Date : August 13, 2024